TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC) - Kudo, M; Ueshima, K; Ikeda, M (Journal of Clinical Oncology, 2021)
et al.